EGFR and breast carcinoma: Nishikawa et al. developed an antihuman heparin-binding EGFR monoclonal antibody targeted DOX encapsulated immunoliposomes which exhibited significantly higher uptake in Vero-H cells and MDA-MB-231 human breast cancer cells over untargeted immunoliposomes.